MedTrace Logo

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

NCT02888301 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-08-12

No results posted yet for this study

Summary

This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system (immunotherapy). PET/CT scans give detailed pictures of areas inside the body. 18F-clofarabine is a drug that contains a radioactive substance that is taken up by cells expressing deoxycytidine kinase (dCK), which is highly expressed in activated immune cells, making them light up during PET/CT scans. Doctors also want to know how 18F-clofarabine is distributed throughout the body before and after treatment with immunotherapies.

Conditions

  • Malignant Neoplasm

Interventions

PROCEDURE

Computed Tomography

Undergo 18F-clofarabine PET/CT

RADIATION

Fluorine F 18 Clofarabine

Given IV

PROCEDURE

Positron Emission Tomography

Undergo 18F-clofarabine PET/CT

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Martin Allen-Auerbach · UCLA / Jonsson Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-12
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02888301 on ClinicalTrials.gov